Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803020 | 0.86 | RIPK1 (0.39) | MEN1KMT2ARIPK1HDAC6ALDH1A1 | |
| SCHEMBL1395075 | 0.84 | FASN (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1394985 | 0.82 | DPP4 (0.37) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL673083 | 0.82 | — | — | |
| SCHEMBL10722471 | 0.82 | MEN1 (0.52) | MEN1KMT2ARIPK1HDAC6ALDH1A1 | |
| SCHEMBL18823854 | 0.79 | RIPK1 (0.44) | MEN1KMT2ARIPK1HDAC6ALDH1A1 | |
| SCHEMBL803076 | 0.77 | RIPK1 (0.48) | MEN1KMT2ARIPK1HDAC6ALDH1A1 | |
| SCHEMBL803077 | 0.77 | RIPK1 (0.48) | MEN1KMT2ARIPK1HDAC6ALDH1A1 | |
| SCHEMBL1278003 | 0.76 | ESR1 (0.39) | RIPK1MAPK1 | |
| SCHEMBL14026991 | 0.76 | DPP7 (0.44) | MEN1KMT2ARIPK1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20210213004-A1 | Compounds | CTXT PTY LTD (AU) | 2021-07-15 | — | — | US | disclosed |
| EP-3813813-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-05-05 | — | — | EP | disclosed |
| US-9069275-B2 | Carrier resins with improved relative humidity sensitivity | XEROX CORPORATION (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140302435-A1 | CARRIER RESINS WITH IMPROVED RELATIVE HUMIDITY SENSITIVITY | National Research Council of Canada ("NRC") (CA) | 2014-10-09 | — | — | US | disclosed |
| EP-1397137-B1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | EP | disclosed |
| US-7125877-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| CN-1272841-A | Novel lactam metalloprotease inhibitors | DU PONT PHARM CO (US) | 2000-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | MEN1 1634/4885KMT2A 3564/4885RIPK1 4494/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | MEN1 697/4885KMT2A 2563/4885RIPK1 4095/4885 |
| US-20210213004-A1 | Compounds | SLC10A1, ABCB11, REN | MEN1 114/4885KMT2A 4080/4885RIPK1 4689/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | MEN1 114/4885KMT2A 4080/4885RIPK1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.